⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 22, 2025

Supplementary Figure 1 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

Rona Yaeger Riccardo Mezzadra Jenna Sinopoli Yu Bian Michelangelo Marasco Esther Kaplun Yijun Gao HuiYong Zhao Arnaud Da Cruz Paula Yingjie Zhu Almudena Chaves Perez Kalyani Chadalavada Edison Tse Sudhir Chowdhry Sydney Bowker Qing Chang Besnik Qeriqi Britta Weigelt Gouri J. Nanjangud Michael F. Berger Hirak Der‐Torossian Kenna Anderes Nicholas D. Socci Jinru Shia Gregory J. Riely Yonina R. Murciano‐Goroff Bob T. Li James G. Christensen Jorge S. Reis‐Filho David B. Solit Elisa de Stanchina Scott W. Lowe Neal Rosen Sandra Misale

View Full Paper

Ask AI

Bookmark

Share

Key Points

Molecular characterization reveals mechanisms of acquired resistance to KRAS G12C–EGFR inhibition.
In vitro models show how colorectal cancer adapts and survives against targeted therapies.
Various acquired resistance mechanisms were identified, including alterations in signaling pathways.
Understanding these mechanisms is crucial for developing more effective colorectal cancer treatments.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

In vitro models demonstrate acquired resistance mechanisms in colorectal cancer, suggesting new targets for treatment.

Abstract

Characterization of acquired resistance in vitro models

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yaeger et al. (2025) studied this question.

synapsesocial.com/papers/689a061be6551bb0af8cd938 https://doi.org/10.1158/2159-8290.29619036

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 4 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer2025
2Supplementary Figure 5 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer2025
3Supplementary Figure 2 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer2025
4Supplementary Figure 6 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer2025
5Supplementary Figure S7 from Efficacy and Imaging Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer2024